A method of estimating the risks from ingested radionuclides.

H D Maillie

Home/Archive/PubMed

PubMed · 3972582

A method of estimating the risks from ingested radionuclides.

H D Maillie

View original source ↗Export metadata ↓

Abstract

A technique is presented for estimating the number of radiation-induced cancers in organs exposed following the ingestion of radionuclides. The method takes into account the dose rate, the sex and the age of the individuals exposed. It assumes a linear no-threshold response and does not incorporate biological repair mechanisms. Two examples are presented which demonstrate that although the dose-equivalent limits may be the same, the different dose rates involved result in different risks.

Explore related subjects

Actuarial Analysis Adolescent Adult Child Cobalt Radioisotopes Female Humans Liver Neoplasms Male Middle Aged Neoplasms, Radiation-Induced Plutonium Radioisotopes Risk Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H D Maillie. 1985. A method of estimating the risks from ingested radionuclides.. https://pubmed.ncbi.nlm.nih.gov/3972582/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Effect on survival of previous angina pectoris after acute myocardial infarction.

Although the present study revealed that previous angina improved in-hospital outcome, no further benefit was observed once the patients left the hospital. The worse long-term prognosis was associated with multi-vessel coronary disease in patients with previous angina.

Actuarial Analysis↗

PubMed1997

Antihypertensive therapy: how to evaluate the benefits.

For more than 30 years, the benefits of antihypertensive therapy have been assessed in randomized trials that monitor cardiovascular events. Even greater benefits can result if prevention of (1) congestive heart failure, (2) left ventricular hypertrophy, and (3) progression to more severe hypertension is taken into consideration. However, quantifying the benefits in order to calculate the cost-effectiveness of treatment is not easy. Taking absolute risk and benefit as the only guide to treatment decisions may result in limiting therapy only to elderly hypertensive patients and hypertensive patients with complications. Furthermore, randomized trials, of which the duration is necessarily short, are likely to underestimate treatment benefits. An alternative to such an approach is the actuarial approach: treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained calculated in this way is much lower than the cost calculated from randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches are taken into consideration by physicians, patients, politicians, and officers of national health systems.

Actuarial Analysis↗

PubMed1997

CMPA fees.

Explore the source record for details and available documents.

Actuarial Analysis↗